SAN DIEGO, June 5 /PRNewswire-FirstCall/ -- Vical Incorporated today announced the enhancement of its management team with the appointment of Ronald B. Moss, M.D., as Vice President, Clinical Development.
Prior to joining Vical, Dr. Moss most recently was Vice-President of Medical Affairs at Telos Pharmaceuticals from 2004 to 2006. From 2003 to 2004, he served as a Senior Director of Worldwide Regulatory Affairs for Vaccines/Biologics in the Merck Research Laboratories Division of Merck and Co., Inc., where he worked on multiple vaccine programs. Dr. Moss joined The Immune Response Corp. in 1994 as Medical Director and advanced through positions of increasing responsibility, concluding as Interim President and CEO in 2002. He had previously served for a year as Assistant Medical Director at Immunization Products Ltd., a joint venture between Rhone-Poulenc Rorer and Immune Response.
Dr. Moss trained first as a Pediatrics Resident at SUNY and then as a Clinical Associate in Allergy and Clinical Immunology at the National Institutes of Health, and is board certified in pediatrics and in allergy & immunology. He earned his M.D. degree in 1987 at the Chicago Medical School, and graduated Phi Beta Kappa with a bachelor’s degree in 1982 from the State University of New York at Stony Brook. Dr. Moss has authored or co-authored more than 60 scientific papers, is an inventor on five patents, and has recently been inducted into the prestigious Alpha Omega Alpha Medical Honor Society. He also served as Chairman of the Scientific Advisory Board for Viral Genetics.
David C. Kaslow, M.D., Vical’s Chief Scientific Officer, said, “We are very pleased to welcome Ron to Vical’s management team. His breadth of experience in preclinical and clinical research and related activities, coupled with his solid background in vaccine development against both infectious diseases and cancer, nicely complements the capabilities of the existing Vical staff and provides additional breadth to support our growing portfolio of development programs.”
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company has developed certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and serve significant unmet medical needs. Additional information on Vical is available at www.vical.com.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company’s focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company’s filings with the Securities and Exchange Commission. These forward-looking statements represent the company’s judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
Contacts: Investors: Media: Alan R. Engbring Susan Neath Vical Incorporated Porter Novelli Life Sciences (858) 646-1127 (858) 527-3486 Website: www.vical.com
Vical Incorporated
CONTACT: Investors, Alan R. Engbring of Vical Incorporated,+1-858-646-1127; or Media, Susan Neath of Porter Novelli Life Sciences,+1-858-527-3486, for Vical Incorporated
Web site: http://www.vical.com/
